Premium
APRI and FIB ‐4 are good predictors of the stage of liver fibrosis in chronic hepatitis B : the Chronic Hepatitis Cohort Study ( CH e CS )
Author(s) -
Teshale E.,
Lu M.,
Rupp L. B.,
Holmberg S. D.,
Moorman A. C.,
Spradling P.,
Vijayadeva V.,
Boscarino J. A.,
Schmidt M. A.,
Gordon S. C.
Publication year - 2014
Publication title -
journal of viral hepatitis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.329
H-Index - 100
eISSN - 1365-2893
pISSN - 1352-0504
DOI - 10.1111/jvh.12279
Subject(s) - fibrosis , medicine , liver fibrosis , liver biopsy , stage (stratigraphy) , gastroenterology , chronic hepatitis , biopsy , immunology , biology , virus , paleontology
Summary We aim to determine the predictive ability of APRI , FIB ‐4 and AST / ALT ratio for staging of liver fibrosis and to differentiate significant fibrosis (F2–F4) from none to minimal fibrosis (F0–F1) in chronic hepatitis B ( CHB ). Liver biopsy results were mapped to an F0–4 equivalent fibrosis stage. Mean APRI and FIB ‐4 scores were significantly higher for each successive fibrosis level from F1 to F4 ( P < 0.05). Based on optimized cut‐offs, the AUROC s in distinguishing F2–F4 from F0 to F1 were 0.81 (0.76–0.87) for APRI , 0.81 (0.75–0.86) for FIB ‐4 and 0.56 (0.49–0.64) for AST / ALT ratio. APRI and FIB ‐4 distinguished F2–F4 from F0 to F1 with good sensitivity and specificity and can be useful for treatment decisions and monitoring progression of fibrosis.